As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted ...

At a time when insurers are backing away from coverage for weight loss medications, President Trump has offered a lifeline ...

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.

Insurance data reveals dramatic regional differences in Ozempic and Mounjaro usage, with obesity-heavy states prescribing GLP ...

During an AHA press conference, Li explained that each component of the triple-receptor agonist compensates for side effects ...

ATLANTA -- Women who had been taking GLP-1 receptor agonist medications prior to becoming pregnant had a lower risk of ...

President Trump's plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular ...

At a White House event Thursday, President Trump announced deals with drug makers Novo Nordisk and Eli Lilly to offer their ...

In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar ...

Novo Nordisk’s closest competitor, Eli Lilly, continues to challenge its dominance in the weight-loss drug market. Eli Lilly, ...

Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded ...